For example, BCL-2 family inhibitors like navitoclax, although effective in clearing senescent cells, are associated with dose-limiting thrombocytopenia due to BCL-xL inhibition in platelets [94]. This evidence concerns the gene BCL2L1 and Thrombocytopenia.